HAIRY CELL LEUKEMIA
Clinical trials for HAIRY CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new HAIRY CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for HAIRY CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New leukemia treatment aims to reduce harsh side effects
Disease control Recruiting nowThis study is testing whether a newer combination of targeted drugs causes fewer serious side effects than the current standard chemotherapy treatment for hairy cell leukemia. Researchers will enroll 86 adults who haven't received any prior treatment for their cancer. They'll com…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called LP-168 in adults whose B-cell blood cancers have returned or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug moves through the body. Researchers will als…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a new two-drug combination (tovorafenib + rituximab) for hairy cell leukemia that has come back or hasn't responded to prior treatment. It will also compare this new combo to the current standard treatment (cladribine + rituximab) for patients who haven't st…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
First-of-its-Kind immune cell therapy trial launches for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing the safety and early effects of a new treatment called anti-CD22 CAR T-cell therapy for adults with hairy cell leukemia that has come back or not responded to other standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab …
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug combo aims to wipe out rare blood cancer
Disease control Recruiting nowThis study is testing a two-step treatment for hairy cell leukemia, a rare blood cancer. First, patients receive a chemotherapy drug (cladribine) to kill cancer cells. Then, they receive an immunotherapy drug (rituximab) to help the immune system clean up any remaining cancer and…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New drug duo aims to outsmart returning blood cancer
Disease control Recruiting nowThis study is testing if a combination of two oral drugs, encorafenib and binimetinib, works better than a previous single drug for adults with hairy cell leukemia that has a specific genetic change (BRAF V600 mutation) and has come back or stopped responding to standard treatmen…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC